ANTIPLATELET EFFECTS OF RECTAL VS ORAL ASPIRIN IN HEALTHY MIDDLE AGED VOLUNTEERS

直肠给药与口服阿司匹林对健康中年志愿者的抗血小板作用

• 批准号: 5216081
• 负责人: SARAH A SPINLER
• 金额: --
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/5216081
• 关键词: aspirin; clinical research; drug administration routes; human subject; human therapy evaluation; oral administration; platelet aggregation; thromboxanes

Despite an absence of data demonstrating efficacy as an antiplatelet agent, rectal aspirin is currently being administered to hospitalized patients with acute myocardial ischemic syndromes who are unconscious or who cannot tolerate oral medications due to emesis or pathological conditions of the gastrointestinal tract. This randomized, double-blinded, placebo-controlled, complete crossover study, is designed to compare the onset and magnitude of effects of ex-vivo platelet aggregation and suppression of thromboxane B2 production, between oral and rectal aspirin (325 mg tablet versus 300 mg suppository) in healthy middle-aged volunteers.

尽管缺乏数据证明作为抗血小板药物的疗效， 剂，直肠阿司匹林目前正在管理住院 意识不清的急性心肌缺血综合征患者，或 因呕吐或病理性呕吐而不能耐受口服药物的患者 胃肠道状况。这种随机的， 设计了一项双盲、安慰剂对照、完全交叉研究 为了比较离体血小板的作用的开始和大小， 聚集和抑制血栓素B2的产生，口服 和直肠阿司匹林（325 mg片剂与300 mg栓剂）在健康 中年志愿者